TY - JOUR
T1 - Recommendations to standardize preanalytical confounding factors in Alzheimer's and Parkinson's disease cerebrospinal fluid biomarkers: an update
AU - del Campo, Marta
AU - Mollenhauer, Brit
AU - Bertolotto, Antonio
AU - Engelborghs, Sebastiaan
AU - Hampel, Harald
AU - Simonsen, Anja Hviid
AU - Kapaki, Elisabeth
AU - Kruse, Niels
AU - Le Bastard, Nathalie
AU - Lehmann, Sylvain
AU - Molinuevo, Jose Luis
AU - Parnetti, Lucilla
AU - Perret-Liaudet, Armand
AU - Saez-Valero, Javier
AU - Saka, Esen
AU - Urbani, Andrea
AU - Vanmechelen, Eugeen
AU - Verbeek, Marcel M.
AU - Visser, Pieter Jelle
AU - Teunissen, Charlotte
PY - 2012/8
Y1 - 2012/8
N2 - Early diagnosis of neurodegenerative disorders such as Alzheimer's (AD) or Parkinson's disease (PD) is needed to slow down or halt the disease at the earliest stage. Cerebrospinal fluid (CSF) biomarkers can be a good tool for early diagnosis. However, their use in clinical practice is challenging due to the high variability found between centers in the concentrations of both AD CSF biomarkers (A beta 42, total tau and phosphorylated tau) and PD CSF biomarker (alpha-synuclein). Such a variability has been partially attributed to different preanalytical procedures between laboratories, thus highlighting the need to establish standardized operating procedures. Here, we merge two previous consensus guidelines for preanalytical confounding factors in order to achieve one exhaustive guideline updated with new evidence for A beta 42, total tau and phosphorylated tau, and a-synuclein. The proposed standardized operating procedures are applicable not only to novel CSF biomarkers in AD and PD, but also to biomarkers for other neurodegenerative disorders.
AB - Early diagnosis of neurodegenerative disorders such as Alzheimer's (AD) or Parkinson's disease (PD) is needed to slow down or halt the disease at the earliest stage. Cerebrospinal fluid (CSF) biomarkers can be a good tool for early diagnosis. However, their use in clinical practice is challenging due to the high variability found between centers in the concentrations of both AD CSF biomarkers (A beta 42, total tau and phosphorylated tau) and PD CSF biomarker (alpha-synuclein). Such a variability has been partially attributed to different preanalytical procedures between laboratories, thus highlighting the need to establish standardized operating procedures. Here, we merge two previous consensus guidelines for preanalytical confounding factors in order to achieve one exhaustive guideline updated with new evidence for A beta 42, total tau and phosphorylated tau, and a-synuclein. The proposed standardized operating procedures are applicable not only to novel CSF biomarkers in AD and PD, but also to biomarkers for other neurodegenerative disorders.
KW - Alzheimer's disease
KW - biomarkers
KW - CSF
KW - early diagnosis
KW - guidelines
KW - Parkinson's disease
KW - preanalytical factors
KW - recommendations
KW - standard operating procedures
U2 - 10.2217/BMM.12.46
DO - 10.2217/BMM.12.46
M3 - Article
SN - 1752-0363
VL - 6
SP - 419
EP - 430
JO - Biomarkers in Medicine
JF - Biomarkers in Medicine
IS - 4
ER -